Management Change/Compensation (Form 8-K)

Departure of President and Chief Executive Officer

Effective August 31, 2026, Mr. Mark Grant will depart from his positions as the President and Chief Executive Officer of Lifeward Ltd. (the "Company") and as a member of the Company's Board of Directors (the "Board"), following the Company's entry into a separation agreement with Mr. Grant on August 31, 2026 (the "Separation Agreement"). Mr. Grant's departure is not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices.

In connection with Mr. Grant's departure and to facilitate an orderly transition, effective September 1, 2026, the Company entered into a consulting agreement with Mr. Grant (the "Consulting Agreement" and, together with the Separation Agreement, the "Separation and Consulting Agreements"). Pursuant to the Consulting Agreement, Mr. Grant will continue to support the Company as a Senior Advisor through September 30, 2026, providing transition assistance and other consulting services in exchange for a consulting fee of $40,000. Pursuant to the Separation Agreement, Mr. Grant's outstanding equity awards will cease vesting as of August 31, 2026, and any unvested equity awards will be forfeited as of such date. The Separation Agreement also contains customary mutual releases and provides for the continuation of certain confidentiality, restrictive covenant, indemnification and other obligations. Mr. Grant will not receive any cash severance payments or continued employee benefits in connection with his separation, other than compensation accrued through his separation date and the consulting fee described above.

The foregoing description of the Separation and Consulting Agreements does not purport to be complete and is qualified in its entirety by reference to the Separation and Consulting Agreements. Copies of the Separation and Consulting Agreements will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the quarter ending September 30, 2026.

Appointment of Interim Chief Executive Officer

On August 31, 2026, the Board appointed Mr. Josh Hexter, age 56, as the Company's Interim Chief Executive Officer and principal executive officer, effective September 1, 2026.

Mr. Hexter currently serves as Chief Operating and Business Officer of Oramed Pharmaceuticals Inc. ("Oramed"), the controlling shareholder of the Company, a position he has held since September 2019. Following his appointment as the Company's Interim Chief Executive Officer, Mr. Hexter will substantially reduce the scope of his responsibilities at Oramed, such that his responsibilities at Oramed are expected to represent approximately 5% of his current responsibilities. Mr. Hexter brings nearly three decades of leadership, business development, operations and management experience in the life sciences industry. From November 2018 to September 2019, Mr. Hexter served as Chief Business Officer of BrainsWay Ltd. From January 2010 to April 2013, Mr. Hexter served as Executive Director of Corporate In-Licensing at BioLineRx Ltd. Mr. Hexter also previously founded and served as Chief Executive Officer of Biosensor Systems Design. Mr. Hexter holds a B.A. from the University of Wisconsin and a master's degree in business from Boston University.

In connection with his appointment, the Company entered into an employment agreement with Mr. Hexter (the "Hexter Employment Agreement"), pursuant to which Mr. Hexter will receive a gross monthly base salary of NIS 100,000, together with a monthly commuting allowance of NIS 5,000 or, alternatively, a company car, and customary benefits in accordance with Israeli law and the Company's policies. Mr. Hexter will also be eligible for an annual bonus in the discretion of the Board and subject to the Company's Compensation Policy. The Hexter Employment Agreement was approved by the Company's Compensation Committee and the Board, effective as of September 1, 2026 and until the Company's next general meeting of shareholders, on terms that are not more favorable than Mr. Grant's compensation arrangements, pursuant to Regulation 1B4 of the Israeli Companies Regulations (Reliefs for Transactions with Interested Parties), 5760-2000, and will be submitted for shareholder approval at the Company's next general meeting of shareholders. The Hexter Employment Agreement provides for a 60-day notice period, subject to the terms thereof, and contains customary confidentiality, intellectual property, non-competition and non-solicitation provisions.